10-Q: Lexaria Bioscience Reports Widened Losses Amid Increased R&D Spending and Going Concern Doubts

Lexaria Bioscience Corp. reported a significant increase in net losses for the nine months ended May 31, 2025, driven by substantial investments in research and development, while also raising substantial doubt about its ability to continue as a going concern.

Summary

• Net loss attributable to Lexaria shareholders for the nine months ended May 31, 2025, was $9,206,003, a significant increase from $3,610,555 for the same period in 2024.
• Revenue increased to $531,923 for the nine months ended May 31, 2025, up from $380,278 in the prior year, primarily due to higher IP licensing fees.
• Research and development expenses surged by $4,963,278 year-over-year, reaching $6,356,637 for the nine months ended May 31, 2025, reflecting increased clinical trial activity.
• Cash and cash equivalents stood at $4,591,761 as of May 31, 2025, down from $6,499,885 at August 31, 2024.
• The company raised $6.0 million in net proceeds from equity offerings during the nine months ended May 31, 2025.
• An accumulated deficit of $60.8 million was reported as of May 31, 2025.
• Lexaria's DehydraTECH-enhanced liraglutide and certain CBD formulations outperformed Rybelsus in a GLP-1 Diabetes Animal Study (WEIGHT-A24-1) for lowering blood sugar and body weight control.
• A human pilot study (GLP-1-H24-3) of DehydraTECH-tirzepatide showed a 47% reduction in adverse events compared to Zepbound, with comparable blood glucose and insulin levels.
• Another human pilot study (GLP-1-H25-5) of DehydraTECH-enhanced liraglutide demonstrated a 22.7% reduction in adverse events, including a 67% reduction in nausea incidence, compared to Saxenda.
• The Australian Phase 1b 12-week chronic clinical study (GLP-1-H24-4) for DehydraTECH formulated cannabidiol, semaglutide, and tirzepatide has completed participant enrollment (120 subjects across 5 arms) and dosing is over half-way completed, with full results expected in Q4 calendar-2025.
• The Hypertension Phase 1b IND Trial (HYPER-H23-1) received FDA 'Study May Proceed' but is currently on hold due to budgetary constraints, contingent on additional capital or a development partner.
• The company re-engaged John Docherty as President and Chief Science Officer and established a Scientific Advisory Board.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including substantial doubt about its ability to continue as a going concern and a widening net loss. While there are promising R&D results for its DehydraTECH technology, particularly in GLP-1/GIP drug delivery, the financial instability and reliance on future capital raises, coupled with a delayed key clinical trial due to budget constraints, overshadow the positive scientific advancements. The overall sentiment is negative due to the severe financial risks.

Positives

• Revenue increased by $151,645 to $531,923 for the nine months ended May 31, 2025, compared to the same period in 2024, driven by higher IP licensing fees.
• DehydraTECH-enhanced liraglutide and certain CBD formulations demonstrated superior performance over Rybelsus in lowering blood sugar and controlling body weight in the GLP-1 Diabetes Animal Study (WEIGHT-A24-1).
• A human pilot study (GLP-1-H24-3) of DehydraTECH-tirzepatide showed a 47% reduction in adverse events compared to Zepbound, with comparable blood glucose and insulin levels, and steady, consistent blood levels.
• Another human pilot study (GLP-1-H25-5) of DehydraTECH-enhanced liraglutide evidenced a 22.7% reduction in adverse events, including a notable 67% reduction in nausea incidence and 31% reduction in gastrointestinal adverse events overall, compared to Saxenda.
• The positive findings from GLP-1-H25-5 support possible pursuit of a 505(b)2 new drug application expedited regulatory development pathway for DehydraTECH-liraglutide.
• Participant enrollment for the Australian Phase 1b 12-week chronic clinical study (GLP-1-H24-4) has been completed with 120 subjects across five arms, and dosing is over half-way completed.
• Long-term stability testing of DehydraTECH compositions shows positive results, meeting internal expectations.
• The company successfully raised $6.0 million in net proceeds from equity offerings during the nine months ended May 31, 2025.
• The company expanded its Scientific Advisory Board with highly respected experts in cardiovascular and neuroscience fields.

Negatives

• Net loss attributable to Lexaria shareholders significantly widened to $9,206,003 for the nine months ended May 31, 2025, from $3,610,555 in the prior year, representing a $5,592,123 increase.
• Research and development expenses increased substantially by $4,963,278, reaching $6,356,637 for the nine months ended May 31, 2025.
• Cash and cash equivalents decreased to $4,591,761 as of May 31, 2025, from $6,499,885 at August 31, 2024.
• Net cash used in operating activities increased to $7,807,889 for the nine months ended May 31, 2025, compared to $3,067,344 for the same prior year period.
• The company reported an accumulated deficit of $60,764,775 as of May 31, 2025.
• The Hypertension Phase 1b IND Trial (HYPER-H23-1), which received FDA 'Study May Proceed' in early calendar-2024, has been placed on hold due to budgetary constraints.
• The company's ability to continue as a going concern is subject to substantial doubt, as existing cash and expected inflows are not sufficient to meet financial obligations for the next twelve months.
• Proceeds from the exercise of warrants were $0 for the nine months ended May 31, 2025, a significant decrease from $6,106,476 in the prior year, indicating reduced investor confidence or less favorable market conditions for warrant exercise.

Risks

• There is substantial doubt about the company's ability to continue as a going concern, as current cash resources and expected license agreement inflows are insufficient to meet financial obligations for the next twelve months.
• The company has consistently incurred recurring losses and negative cash flows from operations, with net losses of $9.2 million for the nine months ended May 31, 2025.
• Future equity or debt financing may not be available on acceptable terms, or at all, which could force the company to reduce spending, curtail or suspend planned programs, or liquidate assets.
• The sale of additional equity may result in further dilution to existing stockholders.
• Entering into additional licensing agreements or collaborations may require relinquishing valuable rights to technologies, future revenue streams, research programs, or product candidates on unfavorable terms.
• Cash requirements may vary materially from current plans due to changes in R&D focus, competitive/technical advances, patent developments, or regulatory changes.
• The commencement of the Hypertension Phase 1b IND Trial (HYPER-H23-1) is contingent upon significant additional capital or attracting a development partner, with unknown timing.

Future Outlook

The company anticipates increased expenditures and continued operating losses and negative cash flows for the foreseeable future due to ongoing R&D programs, particularly human clinical trials for DehydraTECH formulations with GLP-1 drugs and for treating hypertension. While current cash resources are expected to fund operations through the third quarter of fiscal year 2026, existing cash combined with expected license agreement inflows will not be sufficient to meet financial obligations for the twelve-month period following the issuance of these financial statements, necessitating additional equity financing or strategic partnerships.

Management Comments

• "Our current focus is the investigation of the incorporation of our DehydraTECH drug delivery technology with GLP-1 and GIP drugs to enhance absorption and reduce adverse side effects."
• "The recurring losses and negative net cash flows raise substantial doubt as to the Company’s ability to continue as a going concern."
• "We anticipate that our cash resources will be sufficient to fund operations through the third quarter of fiscal year 2026."
• "We have also concluded that our existing cash, combined with inflows expected from executed license agreements, will not be sufficient to meet the Company's financial obligations for the twelve-month period following the issuance of these consolidated financial statements."
• "These positive findings provide support for possible pursuit of a 505(b)2 new drug application expedited regulatory development pathway for DehydraTECH-liraglutide, pending pharmaceutical partner interest that the Company is now searching for."
• "The commencement of this study [Hypertension Phase 1b IND Trial] is contingent upon the receipt of significant additional capital, or our ability to attract a development partner to fund the study, the timing of which is currently unknown."
• "Lexaria continues with applied development and programs in our pharmaceutical division with our primary focus being on optimization of DehydraTECH formulations of GLP-1 drugs, as well as advancing our DehydraTECH-CBD drug to treat hypertension."

Industry Context

Lexaria Bioscience operates in the highly competitive biotechnology and pharmaceutical sectors, specifically focusing on drug delivery platforms. Its DehydraTECH technology aims to improve the bioavailability of active pharmaceutical ingredients (APIs), particularly for GLP-1 and GIP drugs, which are a rapidly growing and high-value segment of the pharmaceutical market for diabetes and weight loss. The company's efforts to reduce adverse events and improve absorption for these drugs position it as a potential innovator in a field dominated by injectable formulations. The pursuit of a 505(b)2 regulatory pathway for DehydraTECH-liraglutide indicates an attempt to expedite market entry by leveraging existing drug data, a common strategy for drug delivery companies. However, the significant R&D expenditures and the 'going concern' warning highlight the capital-intensive nature and inherent financial risks of drug development in this industry.

Comparison to Industry Standards

• In the GLP-1 Diabetes Animal Study (WEIGHT-A24-1), DehydraTECH-enhanced liraglutide and certain CBD formulations demonstrated superior performance in lowering blood sugar and achieving greater body weight control compared to the commercially available Rybelsus formulations.
• A human pilot study (GLP-1-H24-3) showed DehydraTECH-tirzepatide resulted in a 47% reduction in adverse events compared to the Zepbound brand of injected tirzepatide, while achieving comparable overall reductions in blood glucose and increases in insulin levels.
• In human pilot study GLP-1-H25-5, DehydraTECH-enhanced liraglutide evidenced a 22.7% reduction in adverse events, including a 67% reduction in nausea incidence and a 31% reduction in gastrointestinal adverse events overall, compared to the Saxenda brand of injected liraglutide. Blood glucose and insulin levels and patterns were remarkably similar between the DehydraTECH and Saxenda arms.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any material, pending, or existing legal proceedings against itself or its subsidiaries, nor is it involved as a plaintiff in any other material proceeding or pending litigation.

Related Party Transactions

• Lexaria Nicotine LLC, an 83.333% owned subsidiary, has the remaining 16.667% owned by Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing equity financings and potential loss of investment due to substantial doubt about the company's ability to continue as a going concern. Share price is highly sensitive to financial performance and R&D updates.
• **Employees**: The company's ability to continue operations is uncertain, which could impact job security. New management and scientific advisory board appointments may bring new strategic direction.
• **Customers/Licensees**: Continued development of DehydraTECH technology could offer enhanced product formulations, but the company's financial instability might pose risks to long-term partnerships.
• **Suppliers/Creditors**: The 'going concern' warning indicates increased credit risk for suppliers and creditors.
• **Regulatory Authorities**: The company continues to engage with regulatory bodies like the FDA, having received a 'Study May Proceed' letter for a trial, though it is currently on hold.

Next Steps

• Analyze blood and brain tissue PK data from the GLP-1 Diabetes Animal Study (WEIGHT-A24-1) to determine absorption levels.
• Analyze comprehensive liver and kidney function testing and blood chemistry analyses from the WEIGHT-A24-1 study.
• Report full results from the Australian Phase 1b 12-week chronic clinical study (GLP-1-H24-4) during the fourth quarter of calendar-2025.
• Complete pending pharmacokinetic findings from the GLP-1-H25-5 human pilot study.
• Seek pharmaceutical partner interest for DehydraTECH-liraglutide to potentially pursue a 505(b)2 new drug application expedited regulatory development pathway.
• Conclude analytical testing and interpretation of the Biodistribution Study of DehydraTECH-semaglutide.
• Obtain significant additional capital or attract a development partner to fund the Hypertension Phase 1b IND Trial (HYPER-H23-1) to lift its hold.
• Continue to investigate national and international opportunities to pursue expansions and additions to the intellectual property portfolio.
• Fund operations, working capital, and other cash requirements for the next twelve months through equity financing arrangements and potentially from collaborations or strategic partnerships.

Key Dates

Recommendation

Keywords

DehydraTECH, drug delivery, GLP-1, GIP, semaglutide, tirzepatide, liraglutide, cannabidiol, CBD, hypertension, diabetes, weight loss, biotechnology, pharmaceutical, clinical trials, SEC filing, 10-Q, going concern, equity financing, patents, R&D, biopharma